Conditions: Hypercholesterolemia
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 26
Healthy volunteers: yes

Brief summary:
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a metabolite of thromboxane A2 (TxA2), as a marker of in vivo platelet reactivity.

Detailed description:

Arms:
arm 1: ER niacin/laropiprant + Placebo to laropiprant arm 2: ER niacin + Placebo to laropiprant arm 3: laropiprant + Placebo to ER niacin/laropiprant arm 4: Placebo

Interventions: intervention 1: Comparator: niacin + laropiprant intervention 2: Comparator: niacin intervention 3: Comparator: laropiprant intervention 4: Comparator: placebo
Intervention descriptions: intervention 1: ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days intervention 2: ER niacin 2 g tablet once daily for 7 days intervention 3: laropiprant 40 mg once daily for 7 days intervention 4: matching placebo tablets for each of the interventions once daily for 7 days

Protocol document: